Συγγραφείς:
Ludwig, H.
Dimopoulos, M.A.
Moreau, P.
Chng, W.-J.
Goldschmidt, H.
Hájek, R.
Facon, T.
Pour, L.
Niesvizky, R.
Oriol, A.
Rosiñol, L.
Suvorov, A.
Gaidano, G.
Pika, T.
Weisel, K.
Goranova-Marinova, V.
Palumbo, A.
Gillenwater, H.H.
Mohamed, N.
Aggarwal, S.
Feng, S.
Joshua, D.
Λέξεις-κλειδιά:
bortezomib; carfilzomib; dexamethasone; antineoplastic agent; bortezomib; carfilzomib; dexamethasone; oligopeptide, acute kidney failure; adult; adverse drug reaction; aged; anemia; asthenia; controlled study; diarrhea; disease course; drug efficacy; drug safety; drug withdrawal; dyspnea; faintness; fatigue; groups by age; heart failure; heart left ventricle ejection fraction; human; hyperglycemia; hypertension; hypokalemia; Letter; lymphocyte count; major clinical study; multiple cycle treatment; multiple myeloma; neutropenia; peripheral neuropathy; phase 3 clinical trial; pneumonia; priority journal; progression free survival; randomized controlled trial; relapse; thrombocyte count; thrombocytopenia; clinical trial; female; follow up; male; multicenter study; multiple myeloma; pathology; prognosis; survival rate; tumor recurrence, Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Prognosis; Survival Rate
